Which Fat Linked to Heart, Liver, + Cancer Risk?

The fat you can’t see may be shaping far more than your waistline - it’s linked to your heart, liver, cancer risk, and even how fast your brain ages.

A recent Nature Communications study followed adults over time and found that those who sustained visceral fat loss - the deep fat wrapped around organs - had less brain atrophy and better cognitive scores up to a decade later. Changes in BMI or soft, under‑the‑skin subcutaneous fat didn’t show the same benefit, underscoring visceral fat as a unique, modifiable driver of neurodegeneration.

And the brain is just one part of the story. Excess visceral fat is strongly associated with:

• Cardiometabolic disease: Visceral fat releases free fatty acids and inflammatory cytokines directly into portal circulation, driving hepatic insulin resistance, dyslipidemia, metabolic syndrome, and a higher risk of type 2 diabetes and cardiovascular events.

• Chronic inflammation: Deep abdominal fat secretes IL‑6 and other inflammatory mediators into the portal vein, elevating CRP and contributing to atherosclerosis, hypertension, and systemic inflammation.

• Nonalcoholic fatty liver disease (NAFLD): Visceral adipose tissue bathes the liver in free fatty acids and cytokines, promoting steatosis, insulin resistance, and progression toward metabolic dysfunction–associated steatotic liver disease.

• Cancer risk: Visceral obesity is linked with a higher incidence of colorectal, breast, and other cancers, and may worsen prognosis and survival after diagnosis.

• Dementia and cognitive decline: Higher visceral fat in midlife correlates with lower brain volume, higher dementia risk, and greater brain atrophy, even in younger adults.

In other words, visceral fat is not just a cosmetic issue - it’s an inflammatory, metabolic signal that cuts across heart, liver, cancer, and brain health.

How Does GLPerfect Target Visceral Fat Biology?

That’s why GLPerfect is built to go after central, organ‑surrounding fat and its drivers, not just scale weight. Its three core ingredients all point metabolic traffic away from deep belly fat and toward healthier patterns:

• Alpha-lipoic acid (ALA) has been shown in clinical and mechanistic studies to reduce body fat - including visceral depots - while improving fasting glucose, insulin sensitivity, and inflammatory markers associated with central obesity. By improving how your muscles and liver handle glucose and by lowering oxidative stress, ALA helps defuse the metabolic “pressure cooker” that feeds visceral fat.

• Bioavailable berberine improves insulin sensitivity, fasting and post‑meal glucose, and atherogenic lipids, and is now being directly studied for its ability to shrink abdominal visceral adipose tissue and liver fat in individuals with obesity and NAFLD. These shifts in insulin signaling and ectopic fat are precisely the levers tied to less metabolic syndrome, less fatty liver, and lower cardiometabolic and brain‑aging risk.

• EGCG (from green tea) preferentially reduces visceral fat depots (like mesenteric and epididymal fat) in high‑fat diet models, while improving glucose tolerance, enhancing fat oxidation, and activating AMPK‑ and autophagy‑related pathways. That combination not only helps the body burn more from stored fat, but specifically counters the metabolic and inflammatory fingerprint of visceral adiposity.

Taken together, GLPerfect is formulated to address the type of fat most strongly tied to cardiometabolic disease, fatty liver, cancer risk, and accelerated brain aging - the hidden belly fat around your organs - by improving insulin handling, calming inflammation, and shifting how and where you store and burn fat.

It’s not just about looking leaner. It’s about less visceral fat quietly driving inflammation, cardiometabolic risk, and brain shrinkage over the next decade.

Sources

“Alpha-Lipoic Acid (ALA) as a Supplement for Weight Loss.” Journal of Evidence-Based Medicine and Surgery, 2017. https://pmc.ncbi.nlm.nih.gov/articles/PMC5523816/

“How Lipoic Acid Reduces Body Fat.” Life Extension Magazine, 2018. https://www.lifeextension.com/magazine/2021/1/how-lipoic-acid-reduces-body-fat

“Berberine and Adiposity in Diabetes-Free Individuals with Obesity and MASLD: A Randomized Clinical Trial.” JAMA Network Open, 2026. https://pmc.ncbi.nlm.nih.gov/articles/PMC12811813/

“Effects of Berberine in Reducing Abdominal Visceral Adipose Tissue among Individuals with Obesity and NAFLD.” Clinical Trial Protocol, 2025. https://ctv.veeva.com/study/effects-of-berberine-in-reducing-abdominal-visceral-adipose-tissue-among-individuals-with-obesity-an

“Epigallocatechin-3-Gallate Reduces Visceral Adiposity Partly through the AMP-Activated Protein Kinase-Mediated Autophagy in White Adipose Tissue.” International Journal of Obesity, 2020. https://pubmed.ncbi.nlm.nih.gov/33050029/

“Epigallocatechin-3-Gallate Inhibits Obesity, Metabolic Syndrome, and Fatty Liver in High-Fat–Fed Mice.” Journal of Nutrition, 2006. https://pmc.ncbi.nlm.nih.gov/articles/PMC2586893/

“Nonalcoholic Fatty Liver Disease: The Role of Visceral Adipose Tissue.” Hepatology International, 2022. https://pmc.ncbi.nlm.nih.gov/articles/PMC8958250/

“Visceral Adipose Tissue and Residual Cardiovascular Risk.” Nutrients, 2023. https://pmc.ncbi.nlm.nih.gov/articles/PMC10421666/

“Visceral Adiposity Is Associated with Metabolic Profiles Predictive of Cardiometabolic Disease.” Communications Medicine, 2022. https://www.nature.com/articles/s43856-022-00140-5

“Visceral Fat Is Associated with Lower Brain Volume in Healthy Middle-Aged Adults.” Annals of Neurology, 2004. https://pmc.ncbi.nlm.nih.gov/articles/PMC2933649/

“Visceral Fat Adipokine Secretion Is Associated with Systemic Inflammation in Obese Humans.” Diabetes, 2007. https://www.natap.org/2007/HIV/030907_01.htm

“Visceral Obesity and Incident Cancer and Cardiovascular Disease.” Obesity Reviews, 2020. https://pmc.ncbi.nlm.nih.gov/articles/PMC7757158/

“Visceral Adiposity and Cancer: Role in Pathogenesis and Prognosis.” Oncotarget, 2021. https://pmc.ncbi.nlm.nih.gov/articles/PMC8234141/

“Sustained Visceral Fat Loss Is Associated with Attenuated Brain Atrophy and Improved Cognitive Function in Late Midlife.” Nature Communications, 2026. https://pubmed.ncbi.nlm.nih.gov/41888134/